Skip to content

Annexon ANNX Debt-to-assets

Debt-to-assets at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
0.1×0.0×
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
0.0×
Omeros logo
OmerosOMER
0.0×
Vor Biopharma logo
Vor BiopharmaVOR
-0.3×
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
0.0×
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
0.1×-0.3×

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+223%
Enterprise value$718.59M+261%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Calculated from Annexon’s reported figures.

Based on the most recent quarter.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's debt-to-assets?
Annexon (ANNX) reported debt-to-assets of 0.1× in Q1 2026.
How has Annexon's debt-to-assets changed year-over-year?
Annexon's debt-to-assets increased by 3.5% year-over-year, from 0.1× to 0.1×.
What is the long-term trend for Annexon's debt-to-assets?
Over 4 years (2021 to 2025), Annexon's debt-to-assets has grown at a -5.9% compound annual growth rate (CAGR), from 0.1× to 0.1×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.